ValuEngine Upgrades Insys Therapeutics (INSY) to Sell

Insys Therapeutics (NASDAQ:INSY) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Thursday.

INSY has been the subject of a number of other research reports. Zacks Investment Research lowered Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 9th. Royal Bank Of Canada set a $8.00 target price on Insys Therapeutics and gave the stock a “buy” rating in a report on Friday, October 27th. BidaskClub raised Insys Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 26th. Oppenheimer reissued a “hold” rating on shares of Insys Therapeutics in a report on Sunday, November 12th. Finally, TheStreet lowered Insys Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, August 21st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $9.38.

Shares of Insys Therapeutics (INSY) opened at $6.09 on Thursday. Insys Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.02.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN grew its holdings in shares of Insys Therapeutics by 0.5% in the second quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock worth $350,000 after acquiring an additional 126 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Insys Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock worth $1,012,000 after acquiring an additional 475 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Insys Therapeutics by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 21,576 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 938 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Insys Therapeutics by 4.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 37,885 shares of the specialty pharmaceutical company’s stock worth $479,000 after acquiring an additional 1,541 shares during the period. Finally, Teachers Advisors LLC grew its holdings in shares of Insys Therapeutics by 3.7% in the second quarter. Teachers Advisors LLC now owns 45,016 shares of the specialty pharmaceutical company’s stock worth $569,000 after acquiring an additional 1,604 shares during the period. 25.62% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades Insys Therapeutics (INSY) to Sell” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/09/valuengine-upgrades-insys-therapeutics-insy-to-sell.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply